Purchase Order 75N92020P00227

<p>The National Heart Lung and Blood Institute awarded a purchase order to Oxford Nanopore Technologies Inc. for PCR and sequencing equipment valued at $18,648.00 on March 13, 2020, with final completion on August 21, 2020. The order is firm fixed price with no small business set-aside. Performance takes place in Cambridge, Massachusetts.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Oxford Nanopore Technologies Inc. for $50,065.00 on September 7, 2017, for an Oxford Nanopore Starter Pack—a device providing ultra-long read DNA and RNA sequencing using nanopores. Work is performed in Bethesda, Maryland. The order carries a firm fixed price and was scheduled for completion by October 20, 2017.</p>

The National Heart, Lung and Blood Institute's DNA Sequencing and Genomics Core awarded a $12,500 firm fixed price purchase order to Oxford Nanopore Technologies Inc. to provide a GridION license and warranty for the sequencing device identified as GXB03004. As a foreign owned, for-profit organization, Oxford Nanopore Technologies Inc. develops nanopore sequencing technology and delivers the GridION and PromethION sequencing platforms, MINION flow cells, and complementary reagents and kits to...

<p>The National Institutes of Health Clinical Center awarded a purchase order to Oxford Nanopore Technologies Inc. for $14,325.00 on July 22, 2020, for scientific supplies. Place of performance is Cambridge, Massachusetts. The order has a firm fixed price and an ultimate completion date of August 21, 2020. No set-aside was used.</p>

This $12,500.00 firm fixed-price purchase order was awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the National Institutes of Health (NIH), to Oxford Nanopore Technologies Inc., a foreign-owned for-profit biotechnology company. The contract provides a GridION license and warranty for the NHLBI's DNA Sequencing and Genomics Core Facility, with a period of performance from March 17, 2025, to March 16, 2026. Oxford Nanopore Technologies Inc. is a prime...

<p>The NIH Clinical Center awarded a purchase order to Oxford Nanopore Technologies Inc. for $50,005.00 on September 7, 2018, with completion targeted for September 28, 2018. Performance takes place in Bethesda, Maryland. The order procures next-generation genomic sequencing instruments, consumables, or reagents on a firm fixed-price basis. The originating pre-solicitation was posted July 27, 2018, with bids due August 10, 2018.</p>

<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to Oxford Nanopore Technologies Inc. for a DNA/RNA sequencing platform valued at $26,588 on January 28, 2021. The order was firm fixed price with no set-aside designation. Performance occurred in Cambridge, Massachusetts, and the platform was completed by June 9, 2022. The solicitation was posted December 17, 2020, with a due date of December 28, 2020.</p>

<p>The NIH Clinical Center awarded a purchase order to Oxford Nanopore Technologies Inc. for $70,990 on July 31, 2026, for PromethION 2 Sequencer reagents, with completion by October 1, 2026. Performance occurs in New York, NY. The order is firm fixed price with no set-aside designation.</p>

<p>The NIH Clinical Center awarded a purchase order to Oxford Nanopore Technologies Inc. valued at $7,310 on September 21, 2017, with completion targeted for October 30, 2017. Performance is located in Bethesda, Maryland. The order is firm fixed price with no set-aside designation. The source does not specify the equipment, consumables, or reagents procured under this individual order.</p>

This is a $21,835.00 firm fixed-price purchase order awarded by the National Human Genome Research Institute (NHGRI), a civilian agency, to Oxford Nanopore Technologies Inc., a foreign-owned for-profit biotechnology company. The purpose of the award is to provide a reagent needed by Shelise Brooks for the preparation of direct RNA libraries for sequencing on the Oxford Nanopore Promethion system in support of the Collins NF_Isletbetacells project led by Dr. Mike Erdos at NHGRI. The contract...